Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Overview
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Companies Involved in Therapeutics Development
Adgero Biopharmaceuticals Holdings Inc
Feldan Therapeutics Inc
Galderma SA
Genentech Inc
Mayne Pharma Group Ltd
Ono Pharmaceutical Co Ltd
PellePharm Inc
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Drug Profiles
FTX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itracozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rostaporfin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trifarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Product Development Milestones
Featured News & Press Releases
Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome
Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itracozole in BCCNS
Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs
Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference
Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA
Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th Intertiol Investigative Dermatology Meeting
Feb 22, 2018: Adgero Biopharmaceuticals Granted FDA Orphan Drug Desigtion of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome
Jan 11, 2018: HedgePath Pharmaceuticals Receives Orphan Drug Desigtion for SUBA-Itracozole from the European Medicines Agency
Nov 20, 2017: FDA Grants Breakthrough Therapy Desigtion and Orphan Drug Desigtion to Pellepharm for Topical Patidegib in Gorlin Syndrome
Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas
Jul 25, 2017: HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission
May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update
Apr 10, 2017: Positive Clinical Data of Adgero Biopharmaceuticals’ REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Feldan Therapeutics Inc, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Galderma SA, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Genentech Inc, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Mayne Pharma Group Ltd, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by PellePharm Inc, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects, H2 2019
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products, H2 2019